A drug aimed at eliminating depleted, aging cells could help older skin recover from injury much faster, according to a study published in Aging (Aging-US). The paper, titled “Topical treatment with ABT-263 reduces senescence of aging skin and improves subsequent wound healing,” suggests that targeting “zombie cells” in the skin could one day improve healing after surgery, injury or in chronic wounds in older adults.
Eliminating Ageing Cells
As we age, the skin changes at a cellular level. So-called senescent cells accumulate. These are cells that have lost their normal function and ability to divide but are not broken down. Instead, they remain in the tissue and continue to release inflammation-promoting messenger substances. These substances can have a negative impact on the environment and contribute to the fact that regeneration processes such as collagen formation, wound healing and cell regeneration function less well. In the long term, this results in a state of chronic, low-grade inflammation in the tissue, which is often associated with skin ageing, thinning skin and slower repair.
This is where the approach of so-called senolytics comes in, including the active ingredient ABT-263 (Navitoclax). These substances originally come from cancer research and are designed to specifically recognize senescent cells and induce programmed cell death (apoptosis), while healthy cells are spared as much as possible. In the studies described, it was tested whether ABT-263 can also be applied directly to the skin in order to reduce the burden of senescent cells. The idea behind this is that local application could reduce inflammatory signals in the tissue and improve the skin’s ability to repair and renew itself.
At the same time, the active ingredient is not risk-free. ABT-263 can also affect healthy cells, in particular blood platelets, which is why it has not yet been used as a standard therapy. Research is therefore concentrating on finding ways to remove senescent cells as specifically as possible without disrupting important protective functions of the body. Overall, this approach shows that skin ageing is strongly characterized by cellular processes and that the targeted removal of “ageing” cells may open up new possibilities in the future for maintaining skin function for longer – even if clinical application still needs to be investigated further.
A Surprising Healing Boost
The researchers investigated whether ABT-263, a senolytic drug, could reduce this burden when applied directly to aged skin. Senolytics are designed to selectively remove senescent cells associated with aging, inflammation and slowed tissue repair. In the study, aged mice received ABT-263 on their skin for five days. After treatment, the skin showed fewer signs of cellular ageing. When the researchers subsequently caused small wounds, these healed faster in the treated mice than in the untreated mice. By day 24, the wounds were completely healed in 80% of the mice treated with ABT-263, compared to 56% of the untreated mice. One of the more unexpected findings was that ABT-263 briefly increased inflammation in the skin. In many cases, inflammation is considered harmful, especially when it becomes chronic. In this case, however, the brief boost appeared to help prepare the skin for repair.
The treatment appeared to activate healing processes that are normally sluggish in older tissue. Gene activity increased in areas related to wound healing, including collagen production, blood vessel growth, tissue remodeling and other processes needed to close and strengthen damaged skin. This is important because aging skin not only wrinkles or thins. It also responds less well after injury. This slower response can increase the risk of prolonged recovery after surgery, delayed wound healing and complications in people with chronic skin injuries.
Why Topical Treatment is Important
ABT-263 (Navitoclax) has attracted considerable interest from researchers because of its ability to target senescent cells. These cells play a central role in skin ageing and delayed wound healing. However, one problem with systemic senolytics, i.e. those taken orally, is that they act throughout the entire body and can therefore cause side effects, for example on blood formation or other healthy tissue. This is precisely where the advantage of topical application comes into play: If the active ingredient is applied directly to the skin, it can act locally without placing a heavy burden on the entire organism.
The study showed that the local application of ABT-263 had clearly measurable effects in older mice. The number of senescent cells in the skin decreased, while at the same time markers for tissue regeneration and inflammation levels improved. It was interesting to note that this effect occurred primarily in older tissue. In young mice, in which only a few senescent cells are present anyway, the treatment hardly showed any changes. This suggests that the approach is particularly effective where “cellular waste” has actually accumulated over time. This is biologically plausible because senescent cells not only occur more frequently in old age, but also release pro-inflammatory signaling substances more actively. These so-called “SASP factors” (senescence-associated secretory phenotype) can permanently put the surrounding cells in a disturbed state. By reducing these cells, ABT-263 could restore the tissue to a more regeneration-friendly state, which is particularly important for wound healing.
The researchers see potentially important applications in medicine, for example in older patients with an increased risk of poorly healing wounds. The idea of preoperative application is particularly interesting: The skin could be specifically “prepared” before a surgical procedure by reducing senescent cells. This could improve the ability to heal after an operation and reduce the risk of complications. Overall, this study shows that skin ageing is not just a cosmetic problem, but a biological process that directly influences tissue regeneration. In the future, topical senolytics such as ABT-263 could offer a targeted way to improve age-related limitations in wound healing – especially in older people or in medical situations where rapid and stable healing is particularly important.
Recent Research Results Point in the same Direction
Since this work from 2024, the entire field of research has moved further in the direction of local senolytic strategies for skin regeneration. A review article from 2025 in Ageing Research Reviews described cellular senescence as a major factor in skin ageing and skin disease, while also noting that senolytics and related therapies could become useful tools to target harmful senescent cells in the skin.
A study from 2026 took this approach further in wound healing in diabetic patients, a major medical challenge often characterized by chronic inflammation, poor blood vessel growth and cellular senescence. The researchers developed a localized wound dressing with ABT-263 and reported that it reduced senescent cell burden, improved healing in diabetic mice and showed no detectable systemic toxicity in this model.
At the same time, scientists are careful not to portray senescent cells as purely harmful. A review article from 2024 in Frontiers in Immunology emphasized that senescence can play a helpful role in normal wound healing, while persistent senescent cells can contribute to chronic wounds, fibrosis and abnormal healing. The challenge lies in timing and precision: removing the harmful remaining cells without disrupting the beneficial early repair signals.
Promising, But with Important Limitations
The results are promising, but still at an early stage. The ABT-263 skin study was conducted on mice, and more research is needed before scientists know whether the treatment is safe and effective in humans.
Researchers also need to clarify important questions about dosing, timing of application, long-term safety and whether the benefits also apply to human skin, recovery from surgery, diabetic wounds or other slow-healing conditions. Nevertheless, the idea is promising. Overall, this study shows that skin ageing is not just a cosmetic problem, but a biological process that directly affects tissue regeneration. By eliminating cells that inhibit skin aging, topical senolytic treatments could one day help the body repair itself faster and more effectively. For older adults undergoing surgery or suffering from chronic wounds, this could make healing less difficult, less risky and much faster.